Integrating traditional and emerging treatment options in heart failure

American Journal of Health-System Pharmacy

Volumn 61, Issue SUPPL. 2, 2004, Pages

  Nolan Jr , Paul E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aldosterone antagonists; Angiotensin converting enzyme inhibitors; Cardiac drugs; Costs; Digoxin; Diuretics; Economics; Eplerenone; Furosemide; Heart failure; Mechanism of action; Mortality; Protocols; Quality of life; Spironolactone; Sympatholytic agents; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; NEUROHORMONE; NORADRENALIN; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RAMIPRIL; SPIRONOLACTONE; VASODILATOR AGENT; DRUG DERIVATIVE;

CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COGNITIVE THERAPY; CONFERENCE PAPER; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PREFERENCE; DRUG RECEPTOR BINDING; DRUG USE; EXERCISE; GYNECOMASTIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; MASTALGIA; MORALITY; MORBIDITY; OPTIMAL DRUG DOSE; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR AFFINITY; SIDE EFFECT; SUDDEN DEATH; SURVIVAL; SYMPTOM; TRADITIONAL MEDICINE; AGED; BIOAVAILABILITY; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; HALF LIFE TIME; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AGED; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL AVAILABILITY; HALF-LIFE; HUMANS; MALE; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; SPIRONOLACTONE;

EID: 3442892096     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.suppl_2.s14     Document Type: Conference Paper

References (43)

1. Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown & Co.; 1994; 253-6.
2. Yancy CW, Strong M. Contemporary management of heart failure 2002: a review of the new American College of Cardiology/American Heart Association guidelines. Cardiology Special Edition. 2002; 2:22-8. Available at http://www.cardiologyse.com/htmreader.cfm? artid+4590 (accessed 7 Jan 2004).
3. Farrell MH, Foody JM, Krumholz HM. Beta-blockers in heart failure: clinical applications. JAMA. 2002; 287:890-7.
4. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Available at http://www.acc.org/clinical/guidelines/failure/ hf_index.htm (accessed 2004 January 21).
5. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med. 1999; 341: 709-17.
6. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21.
7. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001; 22:1527-60.
8. Kostis JB, Rosen RC, Cosgrove NM et al. Nonpharmacologic therapy improves functional and emotional status in congestive heart failure. Chest. 1994; 106:996-1001.
9. Cooper HA, Dries DL, Davis CE et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999; 100:1311-5.
10. Adams KF Jr. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. Am J Health-Syst Pharm. 2004; 61(Suppl 2):S4-13.
11. Grinstead WC, Francis MJ, Marks GF et al. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol. 1994; 73:881-6.
12. Chui M, Deer M, Bennett S et al. Association between scheduled diuretic adherence and health care utilization in heart failure patients. Pharmacotherapy. 2003; 23:326-32.
13. Routledge HC, Chowdhary S, Townend JN. Heart rate variability - a therapeutic target? J Clin Pharm Ther. 2002; 27:85-92.
14. Nolan J, Batin PD, Andrews R et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-HEART). Circulation. 1998; 98:1510-6.
15. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:525-33.
16. Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003; 289:871-8.
17. Kittleson M, Hurwitz S, Shah MR et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol. 2003; 41: 2029-35.
18. Packer M. Evidence-based management of heart failure: past, present, future. www.medscape.com/viewprogram/2609 (accessed 2004 January 21).
19. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342: 821-8.
20. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327: 669-77.
21. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991; 325:293-302.
22. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316:1429-35.
23. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357:1385-90.
24. Packer M, Bristow MR, Cohn J et al. for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334:1349-55.
25. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001-7.
26. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999; 353:9-13.
27. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation. 2002; 106:2194-9.
28. Pritchett AM, Redfield MM. β-Blockers: new standard therapy for heart failure. Mayo Clin Proc. 2002; 77:839-46.
29. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355: 1582-7.
30. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999; 100:1056-64.
31. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349: 1893-906.
32. Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial infarction - a matter of dose. N Engl J Med. 2003; 349:1963-5. Editorial.
33. McMahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol. 2001; 1:190-6.
34. Swedberg K, Eneroth P, Kjekshus J et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group. Circulation. 1990; 82: 1730-6.
35. Zannad F. An introduction to EPHESUS: rationale, design, and baseline characteristics. www.medscape.com/ viewprogram/2609 (accessed 2004 January 21).
36. Pitt B, Williams G, Remme W et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001; 15:79-87.
37. Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003; 107: 2512-8.
38. Cook CS, Berry LM, Kim DH et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos. 2002; 30:1344-51.
39. Spironolactone for heart failure. Med Lett Drugs Ther. 1999; 41:81-2.
40. Overdiek HW, Merkus FW. The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact. 1987; 5:273-302.
41. Gardiner P, Schrode K, Quinlan D et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989; 29:342-7.
42. Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation. 2003; 108:1790-4.
43. Daniels IR, Layer GT. Gynaecomastia. Eur J Surg. 2001; 167:885-92.